CSL Limited
CSL
Pozycja w akcjach
#367
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Cena akcji
$136.26
Kapitalizacja rynkowa
$65.39B
Zmiana (1 dzień)
-0.61%
Zmiana (1 rok)
-4.06%
Kraj
AU
Handel CSL Limited (CSL)
Kategoria
Healthcare
EPS dla CSL Limited (CSL)
EPS na dzień June 2026 TTM: $-5.29
Według najnowszych raportów finansowych i ceny akcji firmy CSL Limited, obecny EPS (TTM) wynosi $-5.29. Na koniec roku 2024 firma miała EPS w wysokości $5.47, wzrost w porównaniu do do EPS z roku 2023, który wynosił $4.55.
Historia EPS dla CSL Limited od 2000 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-5.29 | -185.32% |
| 2025 | $6.20 | 13.35% |
| 2024 | $5.47 | 20.22% |
| 2023 | $4.55 | -31.37% |
| 2022 | $6.63 | 26.05% |
| 2021 | $5.26 | 13.61% |
| 2020 | $4.63 | 9.20% |
| 2019 | $4.24 | 50.89% |
| 2018 | $2.81 | -4.42% |
| 2017 | $2.94 | 9.29% |
| 2016 | $2.69 | -7.88% |
| 2015 | $2.92 | 8.15% |
| 2014 | $2.70 | 21.09% |
| 2013 | $2.23 | 12.45% |
| 2012 | $1.98 | -0.58% |
| 2011 | $1.99 | 49.05% |
| 2010 | $1.34 | 6.70% |
| 2009 | $1.25 | 7.16% |
| 2008 | $1.17 | 64.09% |
| 2007 | $0.71 | 500.34% |
| 2006 | $0.12 | -78.01% |
| 2005 | $0.54 | 168.22% |
| 2004 | $0.20 | 202.40% |
| 2003 | $0.07 | -21.18% |
| 2002 | $0.08 | -5.06% |
| 2001 | $0.09 | 83.13% |
| 2000 | $0.05 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -427.41% |
US
|
|
| $-7.98 | 50.85% |
US
|
|
| - | - |
CH
|
|
| $27.74 | -624.39% |
NL
|
|
| $13.70 | -358.98% |
BE
|
